Drugs@FDA document
FURADANTIN Letter · NDA 009175 SUPPL-50
Drugs@FDA document · CASPER PHARMA LLC · Feb 2, 2024
Key facts
| Drug name | FURADANTIN |
|---|---|
| Document type | Letter |
| Application | NDA009175 |
| Submission | SUPPL-50 |
| Company | CASPER PHARMA LLC |
| Document date | Feb 2, 2024 |
| FDA document | accessdata.fda.gov |
At a glance
- Labeling-Package Insert Document categories
- 10–99 Documents for this application
- None USP chapters cited in this application's documents
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Drugs@FDA documents
Drugs@FDA posts the letters, labels, reviews and other documents behind each drug application and supplement. Orca1 indexes every document's full text and flags complete response letters.
Source: U.S. Food and Drug Administration (FDA), Drugs@FDA application documents · Source date: